Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)

(2017) G. Von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell-by-Cell Basis

(2008) Simone Diermeier-Daucher et al.   Annals of the New York Academy of Sciences

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

(2008) C. C. Portera et al.   CLINICAL CANCER RESEARCH

Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer

(2008) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY